Unternehmens-Profil
Amgen Inc. is a leading biotechnology company that discovers, develops, manufactures, and delivers human therapeutics worldwide. Its principal products target serious illnesses, including Enbrel for rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for plaque psoriasis, psoriatic arthritis, and Behçet's disease oral ulcers; Prolia for postmenopausal osteoporosis; XGEVA to prevent skeletal-related events; and Repatha to reduce risks of myocardial infarction, stroke, and coronary revascularization. Additional key offerings encompass Nplate for immune thrombocytopenia, KYPROLIS for relapsed or refractory multiple myeloma, Aranesp for anemia, EVENITY for osteoporosis, Vectibix for metastatic colorectal cancer, BLINCYTO for acute lymphoblastic leukemia, TEPEZZA for thyroid eye disease, and KRYSTEXXA for chronic refractory gout. Amgen also markets products like Neulasta, MVASI, AMJEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA, and PROCYSBI. Founded in 1980 and headquartered in Thousand Oaks, California, with approximately 28,000 employees, Amgen plays a pivotal role in the biopharmaceutical sector by addressing unmet needs in oncology, inflammation, cardiovascular disease, bone health, and rare disorders, contributing significantly to global healthcare advancements.
Bewertungs-Kennzahlen
Allgemeine Finanzkennzahlen
Chart · 90 Tage
Letzter Kurs: 329,055 USD· Stand 07.05.2026
News · Amgen Inc.
- 2 Dividend Stocks to Double Up On Right Now
- AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
- RPRX vs. AMGN: Which Stock Is the Better Value Option?
- Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?
- Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know